Related Experiment Video
Updated: Aug 14, 2026
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
Detailed analysis of FLT3 expression levels in acute myeloid leukemia
Florian Kuchenbauer1, Wolfgang Kern, Claudia Schoch
1Department of Internal Medicine III, Ludwig-Maximilians University of Munich, University Hospital Grosshadern, Munich, Germany.
Background And Objectives:
FLT3 mutations are found in up to 30% of cases of acute myeloid leukemia (AML). Although new FLT3 mutations are being increasing by investigated, the role of FLT3 expression levels in wild type as well as in mutated FLT3 has only been infrequently addressed.
Design And Methods:
To further evaluate the role of FLT3 in AML we investigated FLT3 expression levels in 207 adult AML patients and 8 healthy donors by real-time polymerase chain reaction (PCR). The expression levels were correlated with clinical parameters, FAB types, cytogenetics, flow cytometry, microarray analysis, FLT3 mutations, further molecular aberrations and prognosis.
Results:
FLT3 expression levels were different in certain FAB types with increasing levels in the following order: M3
Interpretation And Conclusions:
FLT3 expression levels are correlated with clinical data, genetic subgroups as well as prognosis. Furthermore, our data indicate that FLT3 expression and signaling are closely associated with FAB M5.
Insights
FLT3 expression levels in acute myeloid leukemia (AML) correlate with clinical and genetic factors, and impact prognosis. Higher FLT3 expression is linked to FAB M5 and worse survival in specific patient groups.
Area of Science:
- Hematology
- Molecular Biology
- Oncology
Background:
- FMS-like tyrosine kinase 3 (FLT3) mutations occur in up to 30% of acute myeloid leukemia (AML) cases.
- The role of FLT3 expression levels in both wild-type and mutated FLT3 in AML remains underexplored.
Purpose of the Study:
- To investigate FLT3 expression levels in adult AML patients.
- To correlate FLT3 expression with clinical parameters, FAB types, cytogenetics, and prognosis.
Main Methods:
- Real-time polymerase chain reaction (PCR) was used to measure FLT3 expression in 207 adult AML patients and 8 healthy donors.
- Expression levels were correlated with clinical data, including FAB classification, cytogenetics, flow cytometry, and molecular aberrations.
Main Results:
- FLT3 expression varied across French-American-British (FAB) types, with highest levels in M5 subtypes.
- Expression correlated with FLT3 receptor surface expression (CD135), bone marrow blast percentages, and leukocyte counts.
- No significant difference in FLT3 expression was found between AML with or without FLT3 mutations, but a trend towards worse survival was observed in normal cytogenetics, wild-type FLT3 patients.
Conclusions:
- FLT3 expression levels are significantly associated with clinical data, genetic subgroups, and prognosis in AML.
- FLT3 expression and signaling appear closely linked to FAB M5 subtype.